SEC filings and other documents

Q3 sales beat expectations, but margins fell; price hikes and cost cuts planned for 2027 recovery.

Q2 sales rose 2% but margins fell sharply due to higher costs and increased promotions.

Q1 sales up 1%, FY2026 outlook narrowed, and CEO transition announced.

All proposals passed with strong support and no shareholder questions were raised.

Growth driven by brand strength, innovation, and retail expansion, with margin recovery expected.

Strong 2025 results; 2026 guidance expects growth, margin pressure, and continued category leadership.

Net sales up 6% to $548M; Premier Protein leads growth amid margin pressure and strong innovation.

Q2 net sales up 19% with strong Premier Protein growth; guidance reaffirmed for fiscal 2025.

Raised full-year outlook after Q1 net sales and EBITDA grew 24%+, led by Premier Protein.